Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATTO

Attovia Therapeutics Inc

19.65

Aug 10 • 3:15 PM ET -0.52 (-2.58%)

Healthcare Biotechnology USA Small NASD

Aug 06, 4:11 PMAttovia Therapeutics announces closing of its upsized IPO, raising approximately $332.4 million as underwriters fully exercise their option to purchase additional shares.

Peers: BDRX ELOX SCNI BBLG SLXN VBIO GNPX MBRX AZTR CLDI

Index	-
Market Cap	512.82M
Enterprise Value	643.23M
Income	-
Sales	-
Book/sh	-2.92
Cash/sh	5.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.94
Current Ratio	13.94
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	7.11%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.26%
SMA50	-4.26%
SMA200	-4.26%
Trades

Shs Outstand	43.03M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	22.79 -13.78%
52W Low	18.64 5.42%
Volatility	- -
ATR (14)	2.22
RSI (14)	-
Beta	-
Rel Volume	0.14
Avg Volume	1.85M
Volume	229,582

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-6.43%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	20.17
Price	19.65
Change %	-2.58%

Aug-06-26 04:05PM	Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.94%
05:57AM	Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq (PR Newswire)

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing next-generation biotherapeutics for immune-mediated diseases. It delivers treatments through its platform, ATTOBODY. The company was founded by Tao Fu, Zaneta Odrowaz, and Petter Veiby on December 16, 2022 and is headquartered in San Carlos, CA.

CFATao Fu

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	400,000	6,800,000	1,182,854	Aug 07 09:47 PM
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	200,000	3,400,000	982,854	Aug 07 09:47 PM
Sanofi	10% Owner	Aug 06 '26	Buy	17.00	300,000	5,100,000	1,082,855	Aug 07 03:45 PM
Frazier Life Sciences XI, L.P.	10% Owner	Aug 06 '26	Buy	17.00	588,235	9,999,995	6,154,213	Aug 06 05:35 PM

ADCT Adc Therapeutics SA daily Stock Chart

Peers: NBIX INCY KYMR BMRN CRNX RYTM KRYS AXSM MDGL VKTX

| Held by: IWM IWN IBB VTWO IWC IWO GWX VTWV RSSL IWV

Index	RUT
Market Cap	143.73M
Enterprise Value	29.39M
Income	-136.99M
Sales	79.17M
Book/sh	-1.70
Cash/sh	1.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	193
IPO	May 15, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	1.82
P/B	-
P/C	0.62
P/FCF	-
EV/EBITDA	-
EV/Sales	0.37
Quick Ratio	4.02
Current Ratio	4.09
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.05
EPS next Y	-0.66
EPS next Q	-0.22
EPS this Y	23.57%
EPS next Y	22.61%
EPS next 5Y	37.84%
EPS past 3/5Y	17.66% 21.50%
Sales past 3/5Y	-27.09% -
EPS Y/Y TTM	27.41%
Sales Y/Y TTM	4.43%
EPS Q/Q	40.60%
Sales Q/Q	-9.47%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-4.12% 4.32%

Insider Own	23.54%
Insider Trans	-16.42%
Inst Own	58.58%
Inst Trans	1.23%
ROA	-48.57%
ROE	-
ROIC	-
Gross Margin	89.21%
Oper. Margin	-133.00%
Profit Margin	-173.02%
SMA20	-3.71%
SMA50	-14.30%
SMA200	-65.26%
Trades

Shs Outstand	127.17M
Shs Float	97.25M
Short Float	5.69%
Short Ratio	3.10
Short Interest	5.53M
52W High	4.98 -77.31%
52W Low	0.78 44.95%
Volatility	6.79% 6.93%
ATR (14)	0.09
RSI (14)	40.26
Beta	1.84
Rel Volume	0.23
Avg Volume	1.79M
Volume	370,517

Perf Week	7.62%
Perf Month	-12.40%
Perf Quarter	-67.71%
Perf Half Y	-71.82%
Perf YTD	-67.99%
Perf Year	-57.84%
Perf 3Y	-29.81%
Perf 5Y	-95.84%
Perf 10Y	-
Recom	2.33
Target Price	4.70
Prev Close	1.13
Price	1.13
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$2
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Aug-06-26 07:30AM	ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 (PR Newswire) +5.61%
Jul-06-26 12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge) +5.04%
Jul-01-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire) +6.54%
Jun-30-26 07:15AM	ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial (PR Newswire)
Jun-24-26 09:13AM	ADC Therapeutics To Cut About 17% Of Its Staff A Look At Some Key Details (Stocktwits) -6.96%
07:30AM	Loading…
07:30AM	ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities (PR Newswire)
Jun-04-26 05:27AM	An ADC specialist sinks on safety concerns for blood cancer drug (BioPharma Dive) -57.14%
Jun-03-26 04:05PM	ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PR Newswire)
May-04-26 04:44PM	ADC Therapeutics S.A. Q1 2026 Earnings Call Summary (Moby)
07:30AM	ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire)
May-01-26 09:19AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2026 Earnings (GuruFocus.com)
04:05AM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Apr-27-26 07:30AM	ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 (PR Newswire)
Apr-01-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
Mar-10-26 05:01PM	ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +13.48%
08:35AM	Loading…
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update (PR Newswire)
Mar-09-26 09:17AM	ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Mar-03-26 07:15AM	ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 (PR Newswire)
Mar-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Feb-24-26 07:15AM	ADC Therapeutics to Participate in March Investor Conferences (PR Newswire)
Feb-23-26 07:15AM	ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement (PR Newswire) +7.56%
Feb-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +8.03%
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-13-26 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Jan-08-26 04:05PM	ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
Dec-29-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why (Zacks)
07:55AM	Loading…
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-18-25 01:14AM	RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development (Insider Monkey) +6.27%
Dec-17-25 09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.56%
Dec-15-25 12:00PM	ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-04-25 07:40AM	ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma (TipRanks) -10.38%
Dec-03-25 07:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -14.13%
Dec-02-25 04:05PM	ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial (PR Newswire) +8.49%
Dec-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-18-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-25 04:01PM	ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... (GuruFocus.com) -5.70%
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
07:20AM	ADC Therapeutics SA (ADCT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.28%
07:15AM	ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 (PR Newswire)
Oct-27-25 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Oct-26-25 06:16AM	ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted (Insider Monkey)
Oct-24-25 08:07AM	H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement (Insider Monkey)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
07:30AM	ADC Therapeutics Announces $60 Million Private Placement (PR Newswire)
Oct-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Sep-29-25 12:56AM	ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion (Insider Monkey) +10.14%
Sep-18-25 10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +6.13%
Aug-27-25 07:15AM	ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 03:07AM	ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) +5.10%
Aug-12-25 03:00PM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.70%
07:30AM	ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Aug-11-25 07:00PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:34AM	ADC Therapeutics SA (ADCT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 04:05PM	ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 (PR Newswire)
Aug-04-25 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Aug-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Jul-01-25 04:05PM	ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-16-25 07:15AM	ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire) -5.59%
Jun-12-25 06:45AM	ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PR Newswire)
06:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress (PR Newswire)
Jun-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +13.59%
May-30-25 05:44AM	AbbVies ADC win shows how pharma can break through in solid tumors (Pharma Voice) +11.55%
May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

M.S.Dr. Ameet Mallik M.B.A.

Chief Financial OfficerMr. Jose I. Carmona M.B.A.

Ph.D.Dr. Mohamed Zaki M.D.

Corporate Controller & Chief Accounting OfficerMs. Lisa Michelle Kallebo

Chief Technical OfficerDr. David S. Ege Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Apr 02 '26	Sale	3.28	2,634,506	8,638,545	12,666,731	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 02 '26	Sale	3.28	2,529,491	8,294,201	10,265,297	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Mar 31 '26	Sale	3.75	196,229	736,251	15,470,502	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Mar 31 '26	Sale	3.75	188,407	706,903	12,957,305	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 01 '26	Sale	3.80	169,265	643,038	15,301,237	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 01 '26	Sale	3.80	162,517	617,402	12,794,788	Apr 02 09:00 PM

FATE Fate Therapeutics Inc daily Stock Chart

Peers: ALLO CCCC ALXO BCYC CLLS FHTX CHRS IMRX ZNTL REPL

| Held by: VTI VXF SCHA IWC VHT PRFZ BUSM SCHB AVSC DFMC

Index	-
Market Cap	324.04M
Enterprise Value	226.00M
Income	-129.91M
Sales	6.32M
Book/sh	1.55
Cash/sh	1.50
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	161
IPO	Oct 01, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	51.27
P/B	1.80
P/C	1.85
P/FCF	-
EV/EBITDA	-
EV/Sales	35.76
Quick Ratio	5.85
Current Ratio	5.85
Debt/Eq	0.43
LT Debt/Eq	0.40
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-1.03
EPS next Q	-0.27
EPS this Y	5.93%
EPS next Y	4.70%
EPS next 5Y	2.41%
EPS past 3/5Y	26.67% 11.42%
Sales past 3/5Y	-58.98% -26.71%
EPS Y/Y TTM	26.97%
Sales Y/Y TTM	-52.64%
EPS Q/Q	18.19%
Sales Q/Q	-20.26%
Earnings	May 13 BMO
EPS/Sales Surpr.	7.14% -12.93%

Insider Own	5.16%
Insider Trans	-2.23%
Inst Own	55.79%
Inst Trans	3.33%
ROA	-38.01%
ROE	-55.50%
ROIC	-51.60%
Gross Margin	-97.69%
Oper. Margin	-2207.47%
Profit Margin	-2056.79%
SMA20	6.04%
SMA50	11.88%
SMA200	73.40%
Trades

Shs Outstand	116.27M
Shs Float	110.55M
Short Float	6.62%
Short Ratio	1.90
Short Interest	7.32M
52W High	3.23 -13.93%
52W Low	0.91 205.49%
Volatility	9.42% 8.20%
ATR (14)	0.21
RSI (14)	57.62
Beta	2.57
Rel Volume	0.24
Avg Volume	3.85M
Volume	829,282

Perf Week	11.20%
Perf Month	-10.32%
Perf Quarter	16.32%
Perf Half Y	143.86%
Perf YTD	182.92%
Perf Year	201.71%
Perf 3Y	-14.72%
Perf 5Y	-96.93%
Perf 10Y	19.83%
Recom	2.00
Target Price	5.41
Prev Close	2.80
Price	2.78
Change %	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Resumed	Jefferies	Buy
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform	$7
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90

Show Previous Ratings

Aug-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-26 04:52PM	FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials (Stocktwits) +6.14%
08:30AM	Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate (GlobeNewswire)
Jul-06-26 08:30AM	Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting (GlobeNewswire)
Jul-01-26 04:05PM	Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences (GlobeNewswire) +11.85%
09:00AM	Loading…
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire) +11.57%
Jun-15-26 08:30AM	Fate Therapeutics Appoints Laura Hamill to Board of Directors (GlobeNewswire)
Jun-04-26 08:30AM	Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting (GlobeNewswire)
Jun-02-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.20% -13.62%
Jun-01-26 08:30AM	Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting (GlobeNewswire)
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire) +7.98%
May-21-26 08:30AM	Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases (GlobeNewswire) +14.13%
May-20-26 09:50AM	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) +9.25%
May-13-26 08:35AM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press) -5.11%
08:30AM	Loading…
08:30AM	Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 08:30AM	Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting (GlobeNewswire) -8.79%
May-05-26 08:30AM	Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 (GlobeNewswire) +31.11%
May-04-26 09:00AM	Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases (GlobeNewswire) +17.65%
May-01-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +22.40%
Apr-30-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting (GlobeNewswire)
Apr-16-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting (GlobeNewswire) +6.20%
Apr-09-26 09:00AM	Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences (GlobeNewswire) +7.63%
Apr-02-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
Mar-04-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.84%
Mar-03-26 04:05PM	Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire) -8.67%
10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.41%
09:15AM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
09:00AM	Loading…
09:00AM	Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.69%
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-05-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-25 08:00AM	Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs (GlobeNewswire)
Nov-25-25 08:00AM	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 09:40AM	Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56% -8.40%
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-25 11:30AM	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy (GlobeNewswire)
Oct-14-25 08:00AM	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer (GlobeNewswire) +7.91%
Oct-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.22%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire) -5.31%
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +20.69%
04:30PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates (Zacks) -5.76% -5.99%
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 04:57PM	Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data (Insider Monkey)
07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Ph.D.Dr. Bahram Valamehr M.B.A.

MBAMr. Kamal Adawi M.S.

Chief Legal & Compliance Officer and Corporate SecretaryMs. Cindy R. Tahl J.D.

Senior Vice President of Human Resources & OperationsMs. Jessica Francis

Head of ResearchDr. Martin Hosking

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAHL CINDY	See Remarks	Aug 04 '26	Sale	2.46	38,800	95,405	589,355	Aug 05 04:03 PM
Valamehr Bahram	President and CEO	Aug 04 '26	Sale	2.46	43,947	108,101	591,815	Aug 05 04:01 PM
TAHL CINDY	Officer	Aug 04 '26	Proposed Sale	2.46	38,800	95,405		Aug 04 04:40 PM
Valamehr Bahram	Officer	Aug 04 '26	Proposed Sale	2.46	43,947	108,101		Aug 04 04:34 PM
TAHL CINDY	See Remarks	May 20 '26	Sale	1.88	25,590	48,084	628,155	May 21 04:02 PM
Valamehr Bahram	President and CEO	May 20 '26	Sale	1.88	28,946	54,482	635,762	May 21 04:01 PM
Valamehr Bahram	Officer	May 20 '26	Proposed Sale	1.88	28,946	54,482		May 20 03:41 PM
TAHL CINDY	Officer	May 20 '26	Proposed Sale	1.88	25,590	48,084		May 20 03:38 PM
TAHL CINDY	See Remarks	May 06 '26	Option Exercise	1.25	166,664	207,997	653,745	May 07 04:00 PM
EPSTEIN ROBERT S	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:01 PM
RASTETTER WILLIAM H	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:00 PM
TAHL CINDY	See Remarks	Jan 09 '26	Sale	1.06	10,589	11,275	387,081	Jan 12 04:04 PM
Valamehr Bahram	President and CEO	Jan 09 '26	Sale	1.07	5,190	5,557	329,708	Jan 12 04:03 PM
TAHL CINDY	Officer	Jan 09 '26	Proposed Sale	1.06	10,589	11,275		Jan 09 03:08 PM
Valamehr Bahram	Officer	Jan 09 '26	Proposed Sale	1.07	5,190	5,557		Jan 09 03:08 PM
MENDLEIN JOHN	Former Director	Dec 24 '25	Proposed Sale	1.01	38,428	38,881		Dec 29 02:44 PM

Open in Screener

STTK

Shattuck Labs Inc

7.20

Aug 10 • 3:15 PM ET -0.07 (-0.92%)

Healthcare Biotechnology USA Small NASD

STTK Shattuck Labs Inc daily Stock Chart

Peers: CGON INCY KYMR BMRN CRNX RYTM APGE KRYS AXSM NBIX

| Held by: VTI IWM VXF IWO VTWO VFMO FESM IWC VHT IWN

Index	RUT
Market Cap	650.95M
Enterprise Value	563.42M
Income	-49.87M
Sales	1.00M
Book/sh	1.27
Cash/sh	1.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Oct 09, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	650.95
P/B	5.68
P/C	7.20
P/FCF	-
EV/EBITDA	-
EV/Sales	563.42
Quick Ratio	22.06
Current Ratio	22.06
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-0.64
EPS next Y	-0.50
EPS next Q	-0.12
EPS this Y	31.18%
EPS next Y	-4.07%
EPS next 5Y	6.63%
EPS past 3/5Y	33.69% 4.36%
Sales past 3/5Y	15.32% -36.82%
EPS Y/Y TTM	54.16%
Sales Y/Y TTM	-78.29%
EPS Q/Q	51.04%
Sales Q/Q	-
Earnings	May 07 BMO
EPS/Sales Surpr.	6.14% -

Insider Own	11.50%
Insider Trans	-0.22%
Inst Own	66.39%
Inst Trans	28.64%
ROA	-55.64%
ROE	-61.04%
ROIC	-50.96%
Gross Margin	-264.30%
Oper. Margin	-5258.30%
Profit Margin	-4987.40%
SMA20	1.22%
SMA50	15.87%
SMA200	44.87%
Trades

Shs Outstand	90.37M
Shs Float	79.98M
Short Float	9.76%
Short Ratio	6.05
Short Interest	7.80M
52W High	8.33 -13.53%
52W Low	0.71 911.64%
Volatility	6.96% 8.73%
ATR (14)	0.54
RSI (14)	53.39
Beta	1.10
Rel Volume	0.56
Avg Volume	1.29M
Volume	646,388

Perf Week	-1.19%
Perf Month	8.48%
Perf Quarter	5.15%
Perf Half Y	91.06%
Perf YTD	97.34%
Perf Year	852.39%
Perf 3Y	224.45%
Perf 5Y	-64.57%
Perf 10Y	-
Recom	1.00
Target Price	15.00
Prev Close	7.27
Price	7.20
Change %	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-26	Initiated	Leerink Partners	Outperform	$16
Apr-27-26	Initiated	Cantor Fitzgerald	Overweight
Mar-06-26	Resumed	Needham	Buy	$25
Jan-28-26	Initiated	Piper Sandler	Overweight	$15
Dec-01-25	Upgrade	H.C. Wainwright	Neutral → Buy	$6
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Show Previous Ratings

Jul-24-26 09:32AM	SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls (The Fly)
Jul-20-26 09:39AM	Netflix upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly) -9.43%
Jun-10-26 12:21AM	Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering (GlobeNewswire)
Jun-09-26 04:18PM	Shattuck Labs, Inc. Announces Proposed Public Offering (GlobeNewswire) +9.49%
08:00AM	Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update (GlobeNewswire)
06:00AM	Loading…
Jun-08-26 06:00AM	Shattuck Labs Announces Phase 1 Results for SL-325 (GlobeNewswire) -14.85%
Jun-05-26 04:05PM	Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 (GlobeNewswire)
May-07-26 06:15AM	Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -6.29%
Mar-05-26 06:15AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.82%
Feb-25-26 08:00AM	Shattuck Labs Announces Participation in Upcoming March Investor Conferences (GlobeNewswire) -5.37%
Feb-06-26 08:30AM	Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire) +5.60%
Jan-05-26 10:50PM	Why Shattuck Labs Stock Soared in December (Motley Fool)
Dec-15-25 04:15PM	Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result (Insider Monkey)
Nov-20-25 08:00AM	Shattuck Labs to Participate in Upcoming December Investor Conferences (GlobeNewswire)
04:30PM	Loading…
Nov-06-25 04:30PM	Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-08-25 12:00PM	What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-02-25 07:51AM	Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel (GlobeNewswire)
Sep-19-25 09:55AM	Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? (Zacks)
Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
04:30PM	Loading…
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)

Shattuck Labs, Inc. is a clinical-stage biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Ph.D.Dr. Taylor H. Schreiber M.D.

Chief Financial OfficerMr. Andrew R. Neill M.B.A.

M.D.Dr. Arunthathy Nirmalini Pandite M.B.A.

Vice President of Accounting & SEC reportingMr. Brad Huckabee

Chief Technical OfficerDr. Abhinav A. Shukla Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shukla Abhinav A.	Chief Technical Officer	Jul 06 '26	Option Exercise	3.57	12,153	43,386	98,533	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 02 '26	Option Exercise	3.57	410	1,464	86,790	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 02 '26	Sale	7.01	410	2,874	86,380	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jun 30 '26	Option Exercise	3.57	23,365	83,413	109,745	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 01 '26	Option Exercise	3.57	100	357	86,480	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jun 30 '26	Sale	7.08	23,365	165,424	86,380	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 01 '26	Sale	7.07	100	707	86,380	Jul 02 08:17 PM
Pandite Arundathy N.	Chief Medical Officer	Jun 30 '26	Sale	7.01	30,000	210,300	136,219	Jul 02 08:15 PM
Shukla Abhinav A.	Officer	Jul 02 '26	Proposed Sale	7.01	410	2,874		Jul 02 04:24 PM
Shukla Abhinav A.	Officer	Jul 01 '26	Proposed Sale	7.07	100	707		Jul 01 04:19 PM
Shukla Abhinav A.	Officer	Jun 30 '26	Proposed Sale	7.08	23,365	165,469		Jun 30 04:10 PM
SIEGALL CLAY B	Director	Jun 09 '26	Buy	4.00	62,500	250,000	318,608	Jun 11 05:00 PM
Shukla Abhinav A.	Chief Technical Officer	May 12 '26	Option Exercise	3.57	2,032	7,254	83,290	May 14 08:05 PM
Shukla Abhinav A.	Chief Technical Officer	May 12 '26	Sale	7.01	2,032	14,244	81,258	May 14 08:05 PM
Pandite Arundathy N.	Chief Medical Officer	May 12 '26	Sale	6.61	30,000	198,300	166,219	May 14 08:00 PM
ARUNTHATHY PANDITE	Officer	May 12 '26	Proposed Sale	7.02	60,000	421,200		May 12 04:33 PM
Shukla Abhinav A.	Officer	May 12 '26	Proposed Sale	7.01	2,032	14,236		May 12 04:17 PM
ORBIMED ADVISORS LLC	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:52 PM
Ashiya Mona	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:50 PM

ATTO

Attovia Therapeutics Inc

ADCT

Adc Therapeutics SA

FATE

Fate Therapeutics Inc

STTK

Shattuck Labs Inc

Upgrade your Finviz experience